Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002

dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223). 16039774

2005

dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011

dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. 11847524

2002

dbSNP: rs1057519864
rs1057519864
AR
0.020 GeneticVariation BEFREE A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509-treated patients with progressive disease. 23779130

2013

dbSNP: rs1057519864
rs1057519864
AR
0.020 GeneticVariation BEFREE Using multiple prostate cancer cell lines, we showed that catalytic Topo II inhibitors, ICRF187 and ICRF193 inhibited transcription activities of the wild-type AR, mutant ARs (F876L and W741C) and the AR-V7 splice variant. 26009876

2015

dbSNP: rs1340026226
rs1340026226
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852564
rs137852564
AR
A 0.800 CausalMutation CLINVAR

dbSNP: rs137852564
rs137852564
AR
0.800 GeneticVariation UNIPROT

dbSNP: rs137852567
rs137852567
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. 11847524

2002

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223). 16039774

2005

dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002

dbSNP: rs137852571
rs137852571
AR
0.710 GeneticVariation UNIPROT

dbSNP: rs137852571
rs137852571
AR
0.710 GeneticVariation BEFREE In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met. 12507906

2003

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Mutation (T877A) of the AR gene found in an androgen-sensitive prostate cancer cell line, LNCaP, has been postulated to be involved in hypersensitivity and loss of specificity for androgen. 17312014

2007

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation UNIPROT

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer. 19856921

2009

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups. 25409505

2014

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE The T877A mutant of the AR frequently found in advanced cases of prostate cancer displays an exaggerated stimulation of transcriptional activity by CDK6. 15790678

2005

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A. 18007998

2007

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression. 16636679

2006

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis. 21383160

2011

dbSNP: rs137852578
rs137852578
AR
0.800 GeneticVariation BEFREE This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6). 11906285

2002